全体要約
2023年の腫瘍壊死因子阻害薬市場は、米ドルで評価されており、2030年には市場規模が再調整される見込みです。市場は安定した成長が期待されており、製品の差別化やコスト削減、サプライチェーンの最適化が重要です。企業は研究開発に投資し、戦略的パートナーシップを結ぶ必要があります。
腫瘍壊死因子阻害薬は、関節リウマチやクローン病などの治療に使用されます。市場は、アメリカ、アジア太平洋、ヨーロッパ、中東・アフリカの地域に分かれ、主要な企業にはAbbVie、Amgen、Johnson & Johnsonなどがあります。市場の成長を促進する要因には、政府の規制や技術革新が含まれます。
関連する質問
2023年の腫瘍壊死因子阻害薬市場の価値はUS$百万です。
AbbVie Inc., Amgen Inc., Johnson & Johnson, UCB, Novartis AG, Pfizer, Inc., Merck & Co., Inc., CASI Pharmaceuticals, EPIRUS Biopharmaceuticals, LEO Pharma, PROBIOMED, Shanghai Pharmaceuticals Holding Co., Ltd.
製品差別化, コスト削減, サプライチェーン最適化
概要
この調査報告書は、世界の腫瘍壊死因子阻害剤市場の成長可能性を強調しています。腫瘍壊死因子阻害剤は、今後の市場において安定した成長を示すと予想されています。しかし、製品の差別化、コスト削減、サプライチェーンの最適化は、腫瘍壊死因子阻害剤の普及にとって重要な要素です。市場のプレーヤーは、研究開発に投資し、戦略的パートナーシップを結び、進化する消費者の好みに合わせた提供を行うことで、腫瘍壊死因子阻害剤市場がもたらす膨大な機会を活用する必要があります。
腫瘍壊死因子インヒビター薬は腫瘍壊死因子への生理的反応を抑えるのに役立ちます。
主な特徴：
腫瘍壊死因子阻害薬市場に関する報告書は、さまざまな側面を反映しており、業界に対する貴重な洞察を提供します。
市場規模と成長：この調査報告書は、腫瘍壊死因子阻害薬市場の現在のサイズと成長の概要を提供します。過去のデータ、市場の種類別セグメンテーション（例：ヒュミラ、エンブレル）、地域別の内訳が含まれる可能性があります。
市場の推進要因と課題：この報告書は、腫瘍壊死因子阻害剤市場の成長を促進する要因を特定し分析することができます。例えば、政府の規制、環境問題、技術革新、および変化する消費者の好みなどです。また、業界が直面している課題も強調することができます。これには、インフラの制約、レンジアナイティー、そして高い初期コストが含まれます。
競争環境：この調査報告書は、腫瘍壊死因子阻害剤市場内の競争環境の分析を提供します。主要なプレーヤーのプロフィール、市場シェア、戦略、製品提供が含まれています。また、新興プレーヤーや彼らの市場への潜在的な影響も取り上げることができます。
技術の進展：この調査報告書では、腫瘍壊死因子阻害剤産業における最新の技術進展について深く掘り下げることができます。これには、腫瘍壊死因子阻害剤技術の進歩、腫瘍壊死因子阻害剤の新規参入者、腫瘍壊死因子阻害剤の新規投資、および腫瘍壊死因子阻害剤の未来を形作る他の革新が含まれます。
下流の選好: この報告書は、腫瘍壊死因子阻害薬市場における顧客の選好行動と採用傾向について明らかにします。顧客の購買決定に影響を与える要因や腫瘍壊死因子阻害薬製品への好みが含まれています。
政府の政策およびインセンティブ：本研究報告書は、腫瘍壊死因子抑制薬市場に対する政府の政策およびインセンティブの影響を分析しています。これには、規制の枠組み、補助金、税のインセンティブ、腫瘍壊死因子抑制薬市場を促進することを目的としたその他の措置の評価が含まれる可能性があります。また、報告書は、これらの政策が市場成長を促進する効果についても評価しています。
環境影響と持続可能性：この調査報告書では、腫瘍壊死因子阻害薬市場の環境影響と持続可能性の側面を評価しています。
市場予測と将来の見通し：実施された分析に基づき、研究報告書は腫瘍壊死因子阻害薬業界の市場予測と見通しを提供します。これには、市場規模、成長率、地域動向、技術の進展および政策の動向に関する予測が含まれます。
推奨事項と機会：報告書は、業界の利害関係者、政策立案者、および投資家への推奨事項で締めくくられます。新たに出現するトレンドを活かし、課題を克服し、腫瘍壊死因子阻害薬市場の成長と発展に貢献するための市場参加者にとっての潜在的な機会を強調しています。
市場セグメンテーション：
腫瘍壊死因子阻害薬市場は、タイプおよびアプリケーションによって分かれています。2019年から2030年の期間において、セグメント間の成長は、タイプおよびアプリケーション別の消費価値に関する正確な計算と予測を提供します。
タイプ別セグメンテーション
ヒュミラ
エンブレル
レミケード
シンポニー
シムジア
バイオシミラー
アプリケーション別のセグメンテーション
関節リウマチ
乾癬性関節炎
若年性特発性関節炎
クローン病
潰瘍性大腸炎
その他
このレポートでは、市場を地域別に分割します。
アメリカ大陸
アメリカ合衆国
カナダ
メキシコ
ブラジル
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
中東およびアフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下のプロファイルに記載されている企業は、主要な専門家からの意見や企業のカバレッジ、製品ポートフォリオ、市場浸透率を分析した結果に基づいて選定されています。
アッヴィ社
アムジェン社
ジョンソン・エンド・ジョンソン
UCB
ノバルティスAG
ファイザー株式会社
メルク・アンド・カンパニー、インク。
CASIファーマシューティカルズ
エピルスバイオファーマシューティカルズ
LEOファーマ
プロビオメッド
上海医薬グループ株式会社
本報告書で扱われる主要な質問
グローバルな腫瘍壊死因子阻害薬市場の10年見通しは何ですか？
腫瘍壊死因子阻害薬市場の成長を促進している要因は何ですか、世界的および地域別に？
市場と地域別に、最も急速な成長が期待される技術はどれですか？
腫瘍壊死因子阻害薬市場の機会は、最終市場の規模によってどのように異なりますか？
腫瘍壊死因子阻害剤の種類、用途の内訳はどうなっていますか？
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 調査範囲
1.1 市場イントロダクション
1.2 対象年
1.3 調査目的
1.4 市場調査手法
1.5 調査プロセスとデータソース
1.6 経済指標
1.7 通貨
1.8 市場予測における留意事項
2 エグゼクティブサマリー
2.1 世界市場概要
2.1.1 グローバルの腫瘍壊死因子阻害薬、年間売上、2019年～2030年
2.1.2 腫瘍壊死因子阻害薬の世界市場の現状分析・将来予測、地理別、2019年、2023年および2030年
2.1.3 腫瘍壊死因子阻害薬の世界市場の現状分析・将来予測、国・地域別、2019年、2023年および2030年
2.2 腫瘍壊死因子阻害薬セグメント、タイプ別
2.2.1 ヒュミラ
2.2.2 エンブレル
2.2.3 レミケード
2.2.4 シンポニー
2.2.5 チムジア
2.2.6 バイオシミラー
2.3 腫瘍壊死因子阻害薬の売上、タイプ別
2.3.1 グローバルにおける腫瘍壊死因子阻害薬の売上・市場シェア、タイプ別（2019年～2024年）
2.3.2 腫瘍壊死因子阻害薬のグローバルレベニュー・市場シェア、タイプ別（2019～2024年）
2.3.3 グローバルの腫瘍壊死因子阻害薬、販売価格（タイプ別）（2019年～2024年）
2.4 腫瘍壊死因子阻害薬セグメント、用途別
2.4.1 関節リウマチ
2.4.2 乾癬性関節炎
2.4.3 若年性特発性関節炎
2.4.4 クローン病
2.4.5 潰よう性大腸炎
2.4.6 その他
2.5 腫瘍壊死因子阻害薬の売上、用途別
2.5.1 グローバルの腫瘍壊死因子阻害薬、収益・市場シェア（用途別）（2019年～2024年）
2.5.2 腫瘍壊死因子阻害薬のグローバルレベニュー・市場シェア、用途別（2019～2024年）
2.5.3 グローバルの腫瘍壊死因子阻害薬、販売価格（用途別）（2019年～2024年）
3 グローバルにおける腫瘍壊死因子阻害薬、企業別
3.1 グローバルにおける腫瘍壊死因子阻害薬市場のブレークダウンデータ、企業別
3.1.1 グローバルにおける腫瘍壊死因子阻害薬の年間売上、企業別（2019年～2024年）
3.1.2 グローバルにおける腫瘍壊死因子阻害薬の売上・市場シェア、企業別（2019年～2024年）
3.2 グローバルにおける腫瘍壊死因子阻害薬の年間収益、企業別（2019年～2024年）
3.2.1 グローバルにおける腫瘍壊死因子阻害薬市場の収益規模、企業別（2019年～2024年）
3.2.2 グローバルにおける腫瘍壊死因子阻害薬市場の収益シェア、企業別（2019年～2024年）
3.3 グローバルにおける腫瘍壊死因子阻害薬の販売価格、企業別
3.4 腫瘍壊死因子阻害薬の主要メーカー、生産地域分布、販売地域、製品タイプ
3.4.1 腫瘍壊死因子阻害薬の主要メーカー、製品と拠点の分布
3.4.2 プレイヤーが提供している腫瘍壊死因子阻害薬製品
3.5 市場集中度分析
3.5.1 競合情勢分析
3.5.2 集中度レシオ（CR3、CR5、CR10）（2019年～2024年）
3.6 新製品・潜在的参入
3.7 M&A、拡大
4 腫瘍壊死因子阻害薬の世界市場過去推移レビュー、地理別
4.1 腫瘍壊死因子阻害薬の世界市場規模の過去推移、地理別（2019年～2024年）
4.1.1 グローバルにおける腫瘍壊死因子阻害薬の年間売上、地理別（2019年～2024年）
4.1.2 グローバルにおける腫瘍壊死因子阻害薬の年間収益、地理別（2019年～2024年）
4.2 腫瘍壊死因子阻害薬の世界市場規模の過去推移、国・地域別（2019年～2024年）
4.2.1 グローバルにおける腫瘍壊死因子阻害薬の年間売上、国・地域別（2019年～2024年）
4.2.2 グローバルにおける腫瘍壊死因子阻害薬の年間収益、国・地域別（2019年～2024年）
4.3 アメリカズにおける腫瘍壊死因子阻害薬の売上成長
4.4 APACにおける腫瘍壊死因子阻害薬の売上成長
4.5 ヨーロッパにおける腫瘍壊死因子阻害薬の売上成長
4.6 中東・アフリカにおける腫瘍壊死因子阻害薬の売上成長
5 アメリカズ
5.1 アメリカズにおける腫瘍壊死因子阻害薬の売上、国別
5.1.1 アメリカズにおける腫瘍壊死因子阻害薬の売上規模、国別（2019年～2024年）
5.1.2 アメリカズにおける腫瘍壊死因子阻害薬市場の収益規模、国別（2019年～2024年）
5.2 アメリカズにおける腫瘍壊死因子阻害薬の売上、タイプ別
5.3 アメリカズにおける腫瘍壊死因子阻害薬の売上、用途別
5.4 米国
5.5 カナダ
5.6 メキシコ
5.7 ブラジル
6 APAC
6.1 APACにおける腫瘍壊死因子阻害薬の売上、地域別
6.1.1 APACにおける腫瘍壊死因子阻害薬の売上規模、地域別（2019年～2024年）
6.1.2 APACにおける腫瘍壊死因子阻害薬市場の収益規模、地域別（2019年～2024年）
6.2 APACにおける腫瘍壊死因子阻害薬の売上、タイプ別
6.3 APACにおける腫瘍壊死因子阻害薬の売上、用途別
6.4 中国
6.5 日本
6.6 韓国
6.7 東南アジア
6.8 インド
6.9 オーストラリア
6.10 中国の台湾
7 ヨーロッパ
7.1 ヨーロッパにおける腫瘍壊死因子阻害薬、国別
7.1.1 ヨーロッパにおける腫瘍壊死因子阻害薬の売上規模、国別（2019年～2024年）
7.1.2 ヨーロッパにおける腫瘍壊死因子阻害薬市場の収益規模、国別（2019年～2024年）
7.2 ヨーロッパにおける腫瘍壊死因子阻害薬の売上、タイプ別
7.3 ヨーロッパにおける腫瘍壊死因子阻害薬の売上、用途別
7.4 ドイツ
7.5 フランス
7.6 英国
7.7 イタリア
7.8 ロシア
8 中東・アフリカ
8.1 中東・アフリカにおける腫瘍壊死因子阻害薬、国別
8.1.1 中東・アフリカにおける腫瘍壊死因子阻害薬の売上規模、国別（2019年～2024年）
8.1.2 中東・アフリカにおける腫瘍壊死因子阻害薬市場の収益規模、国別（2019年～2024年）
8.2 中東・アフリカにおける腫瘍壊死因子阻害薬の売上、タイプ別
8.3 中東・アフリカにおける腫瘍壊死因子阻害薬の売上、用途別
8.4 エジプト
8.5 南アフリカ
8.6 イスラエル
8.7 トルコ
8.8 GCC地域
9 市場ドライバー・課題・トレンド
9.1 市場ドライバー・成長機会
9.2 市場課題・リスク
9.3 業界トレンド
10 製造コスト構造分析
10.1 原料・サプライヤー
10.2 腫瘍壊死因子阻害薬の製造コスト構造分析
10.3 腫瘍壊死因子阻害薬の製造プロセス分析
10.4 腫瘍壊死因子阻害薬のインダストリーチェーン構造
11 マーケティング・流通・顧客
11.1 販売チャネル
11.1.1 直接チャネル
11.1.2 間接チャネル
11.2 腫瘍壊死因子阻害薬の流通業者
11.3 腫瘍壊死因子阻害薬の顧客
12 腫瘍壊死因子阻害薬の世界市場予測レビュー、地理別
12.1 グローバルにおける腫瘍壊死因子阻害薬の市場規模予測、地域別
12.1.1 グローバルの腫瘍壊死因子阻害薬、市場予測（地域別）（2025年～2030年）
12.1.2 グローバルの腫瘍壊死因子阻害薬、年間収益予測（地域別）（2025年～2030年）
12.2 アメリカズにおける予測、国別
12.3 APACにおける予測、地域別
12.4 ヨーロッパにおける予測、国別
12.5 中東・アフリカにおける予測、国別
12.6 グローバルにおける腫瘍壊死因子阻害薬の市場予測、タイプ別
12.7 グローバルにおける腫瘍壊死因子阻害薬の市場予測、用途別
13 キープレイヤー分析
13.1 AbbVie Inc
13.2 Amgen Inc
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson：企業情報
13.3.2 Johnson & Johnson：腫瘍壊死因子阻害薬製品ポートフォリオと特徴
13.3.3 Johnson & Johnson：腫瘍壊死因子阻害薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.3.4 Johnson & Johnson：主要事業概要
13.3.5 Johnson & Johnson：直近の展開
13.4 UCB
13.4.1 UCB：企業情報
13.4.2 UCB：腫瘍壊死因子阻害薬製品ポートフォリオと特徴
13.4.3 UCB：腫瘍壊死因子阻害薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.4.4 UCB：主要事業概要
13.4.5 UCB：直近の展開
13.5 Novartis AG
13.5.1 Novartis AG：企業情報
13.5.2 Novartis AG：腫瘍壊死因子阻害薬製品ポートフォリオと特徴
13.5.3 Novartis AG：腫瘍壊死因子阻害薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.5.4 Novartis AG：主要事業概要
13.5.5 Novartis AG：直近の展開
13.6 Pfizer, Inc
13.7 Merck & Co\., Inc
13.8 CASI Pharmaceuticals
13.8.1 CASI Pharmaceuticals：企業情報
13.8.2 CASI Pharmaceuticals：腫瘍壊死因子阻害薬製品ポートフォリオと特徴
13.8.3 CASI Pharmaceuticals：腫瘍壊死因子阻害薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.8.4 CASI Pharmaceuticals：主要事業概要
13.8.5 CASI Pharmaceuticals：直近の展開
13.9 EPIRUS Biopharmaceuticals
13.9.1 EPIRUS Biopharmaceuticals：企業情報
13.9.2 EPIRUS Biopharmaceuticals：腫瘍壊死因子阻害薬製品ポートフォリオと特徴
13.9.3 EPIRUS Biopharmaceuticals：腫瘍壊死因子阻害薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.9.4 EPIRUS Biopharmaceuticals：主要事業概要
13.9.5 EPIRUS Biopharmaceuticals：直近の展開
13.10 LEO Pharma
13.10.1 LEO Pharma：企業情報
13.10.2 LEO Pharma：腫瘍壊死因子阻害薬製品ポートフォリオと特徴
13.10.3 LEO Pharma：腫瘍壊死因子阻害薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.10.4 LEO Pharma：主要事業概要
13.10.5 LEO Pharma：直近の展開
13.11 PROBIOMED
13.11.1 PROBIOMED：企業情報
13.11.2 PROBIOMED：腫瘍壊死因子阻害薬製品ポートフォリオと特徴
13.11.3 PROBIOMED：腫瘍壊死因子阻害薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.11.4 PROBIOMED：主要事業概要
13.11.5 PROBIOMED：直近の展開
13.12 Shanghai Pharmaceuticals Holding Co\., Ltd
14 調査の結果・結論
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
The research report highlights the growth potential of the global Tumor Necrosis Factor Inhibitor Drug market. Tumor Necrosis Factor Inhibitor Drug are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Tumor Necrosis Factor Inhibitor Drug. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Tumor Necrosis Factor Inhibitor Drug market.
Tumor necrosis factor inhibitor drug helps to stop physiologic response to tumor necrosis factor.
Key Features:
The report on Tumor Necrosis Factor Inhibitor Drug market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Tumor Necrosis Factor Inhibitor Drug market. It may include historical data, market segmentation by Type (e.g., Humira, Enbrel), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Tumor Necrosis Factor Inhibitor Drug market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Tumor Necrosis Factor Inhibitor Drug market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Tumor Necrosis Factor Inhibitor Drug industry. This include advancements in Tumor Necrosis Factor Inhibitor Drug technology, Tumor Necrosis Factor Inhibitor Drug new entrants, Tumor Necrosis Factor Inhibitor Drug new investment, and other innovations that are shaping the future of Tumor Necrosis Factor Inhibitor Drug.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Tumor Necrosis Factor Inhibitor Drug market. It includes factors influencing customer ' purchasing decisions, preferences for Tumor Necrosis Factor Inhibitor Drug product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Tumor Necrosis Factor Inhibitor Drug market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Tumor Necrosis Factor Inhibitor Drug market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Tumor Necrosis Factor Inhibitor Drug market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Tumor Necrosis Factor Inhibitor Drug industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Tumor Necrosis Factor Inhibitor Drug market.
Market Segmentation:
Tumor Necrosis Factor Inhibitor Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Humira
Enbrel
Remicade
Simponi
Cimzia
Biosimilars
Segmentation by application
Rheumatoid Arthritis
Psoriatic Arthritis
Juvenile Idiopathic Arthritis
Crohn’s Disease
Ulcerative Colitis
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie Inc.
Amgen Inc.
Johnson & Johnson
UCB
Novartis AG
Pfizer, Inc.
Merck & Co., Inc.
CASI Pharmaceuticals
EPIRUS Biopharmaceuticals
LEO Pharma
PROBIOMED
Shanghai Pharmaceuticals Holding Co., Ltd.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Tumor Necrosis Factor Inhibitor Drug market?
What factors are driving Tumor Necrosis Factor Inhibitor Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Tumor Necrosis Factor Inhibitor Drug market opportunities vary by end market size?
How does Tumor Necrosis Factor Inhibitor Drug break out type, application?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Tumor Necrosis Factor Inhibitor Drug Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Tumor Necrosis Factor Inhibitor Drug by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Tumor Necrosis Factor Inhibitor Drug by Country/Region, 2019, 2023 & 2030
2.2 Tumor Necrosis Factor Inhibitor Drug Segment by Type
2.2.1 Humira
2.2.2 Enbrel
2.2.3 Remicade
2.2.4 Simponi
2.2.5 Cimzia
2.2.6 Biosimilars
2.3 Tumor Necrosis Factor Inhibitor Drug Sales by Type
2.3.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2019-2024)
2.3.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue and Market Share by Type (2019-2024)
2.3.3 Global Tumor Necrosis Factor Inhibitor Drug Sale Price by Type (2019-2024)
2.4 Tumor Necrosis Factor Inhibitor Drug Segment by Application
2.4.1 Rheumatoid Arthritis
2.4.2 Psoriatic Arthritis
2.4.3 Juvenile Idiopathic Arthritis
2.4.4 Crohn’s Disease
2.4.5 Ulcerative Colitis
2.4.6 Others
2.5 Tumor Necrosis Factor Inhibitor Drug Sales by Application
2.5.1 Global Tumor Necrosis Factor Inhibitor Drug Sale Market Share by Application (2019-2024)
2.5.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue and Market Share by Application (2019-2024)
2.5.3 Global Tumor Necrosis Factor Inhibitor Drug Sale Price by Application (2019-2024)
3 Global Tumor Necrosis Factor Inhibitor Drug by Company
3.1 Global Tumor Necrosis Factor Inhibitor Drug Breakdown Data by Company
3.1.1 Global Tumor Necrosis Factor Inhibitor Drug Annual Sales by Company (2019-2024)
3.1.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Company (2019-2024)
3.2 Global Tumor Necrosis Factor Inhibitor Drug Annual Revenue by Company (2019-2024)
3.2.1 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Company (2019-2024)
3.2.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Company (2019-2024)
3.3 Global Tumor Necrosis Factor Inhibitor Drug Sale Price by Company
3.4 Key Manufacturers Tumor Necrosis Factor Inhibitor Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Tumor Necrosis Factor Inhibitor Drug Product Location Distribution
3.4.2 Players Tumor Necrosis Factor Inhibitor Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Tumor Necrosis Factor Inhibitor Drug by Geographic Region
4.1 World Historic Tumor Necrosis Factor Inhibitor Drug Market Size by Geographic Region (2019-2024)
4.1.1 Global Tumor Necrosis Factor Inhibitor Drug Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Tumor Necrosis Factor Inhibitor Drug Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Tumor Necrosis Factor Inhibitor Drug Market Size by Country/Region (2019-2024)
4.2.1 Global Tumor Necrosis Factor Inhibitor Drug Annual Sales by Country/Region (2019-2024)
4.2.2 Global Tumor Necrosis Factor Inhibitor Drug Annual Revenue by Country/Region (2019-2024)
4.3 Americas Tumor Necrosis Factor Inhibitor Drug Sales Growth
4.4 APAC Tumor Necrosis Factor Inhibitor Drug Sales Growth
4.5 Europe Tumor Necrosis Factor Inhibitor Drug Sales Growth
4.6 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Growth
5 Americas
5.1 Americas Tumor Necrosis Factor Inhibitor Drug Sales by Country
5.1.1 Americas Tumor Necrosis Factor Inhibitor Drug Sales by Country (2019-2024)
5.1.2 Americas Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2019-2024)
5.2 Americas Tumor Necrosis Factor Inhibitor Drug Sales by Type
5.3 Americas Tumor Necrosis Factor Inhibitor Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor Necrosis Factor Inhibitor Drug Sales by Region
6.1.1 APAC Tumor Necrosis Factor Inhibitor Drug Sales by Region (2019-2024)
6.1.2 APAC Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2019-2024)
6.2 APAC Tumor Necrosis Factor Inhibitor Drug Sales by Type
6.3 APAC Tumor Necrosis Factor Inhibitor Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Tumor Necrosis Factor Inhibitor Drug by Country
7.1.1 Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country (2019-2024)
7.1.2 Europe Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2019-2024)
7.2 Europe Tumor Necrosis Factor Inhibitor Drug Sales by Type
7.3 Europe Tumor Necrosis Factor Inhibitor Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug by Country
8.1.1 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country (2019-2024)
8.1.2 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2019-2024)
8.2 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales by Type
8.3 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Tumor Necrosis Factor Inhibitor Drug
10.3 Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitor Drug
10.4 Industry Chain Structure of Tumor Necrosis Factor Inhibitor Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Tumor Necrosis Factor Inhibitor Drug Distributors
11.3 Tumor Necrosis Factor Inhibitor Drug Customer
12 World Forecast Review for Tumor Necrosis Factor Inhibitor Drug by Geographic Region
12.1 Global Tumor Necrosis Factor Inhibitor Drug Market Size Forecast by Region
12.1.1 Global Tumor Necrosis Factor Inhibitor Drug Forecast by Region (2025-2030)
12.1.2 Global Tumor Necrosis Factor Inhibitor Drug Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Tumor Necrosis Factor Inhibitor Drug Forecast by Type
12.7 Global Tumor Necrosis Factor Inhibitor Drug Forecast by Application
13 Key Players Analysis
13.1 AbbVie Inc.
13.1.1 AbbVie Inc. Company Information
13.1.2 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications
13.1.3 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 AbbVie Inc. Main Business Overview
13.1.5 AbbVie Inc. Latest Developments
13.2 Amgen Inc.
13.2.1 Amgen Inc. Company Information
13.2.2 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications
13.2.3 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Amgen Inc. Main Business Overview
13.2.5 Amgen Inc. Latest Developments
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson Company Information
13.3.2 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications
13.3.3 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Johnson & Johnson Main Business Overview
13.3.5 Johnson & Johnson Latest Developments
13.4 UCB
13.4.1 UCB Company Information
13.4.2 UCB Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications
13.4.3 UCB Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 UCB Main Business Overview
13.4.5 UCB Latest Developments
13.5 Novartis AG
13.5.1 Novartis AG Company Information
13.5.2 Novartis AG Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications
13.5.3 Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Novartis AG Main Business Overview
13.5.5 Novartis AG Latest Developments
13.6 Pfizer, Inc.
13.6.1 Pfizer, Inc. Company Information
13.6.2 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications
13.6.3 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Pfizer, Inc. Main Business Overview
13.6.5 Pfizer, Inc. Latest Developments
13.7 Merck & Co., Inc.
13.7.1 Merck & Co., Inc. Company Information
13.7.2 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications
13.7.3 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Merck & Co., Inc. Main Business Overview
13.7.5 Merck & Co., Inc. Latest Developments
13.8 CASI Pharmaceuticals
13.8.1 CASI Pharmaceuticals Company Information
13.8.2 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications
13.8.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 CASI Pharmaceuticals Main Business Overview
13.8.5 CASI Pharmaceuticals Latest Developments
13.9 EPIRUS Biopharmaceuticals
13.9.1 EPIRUS Biopharmaceuticals Company Information
13.9.2 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications
13.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 EPIRUS Biopharmaceuticals Main Business Overview
13.9.5 EPIRUS Biopharmaceuticals Latest Developments
13.10 LEO Pharma
13.10.1 LEO Pharma Company Information
13.10.2 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications
13.10.3 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 LEO Pharma Main Business Overview
13.10.5 LEO Pharma Latest Developments
13.11 PROBIOMED
13.11.1 PROBIOMED Company Information
13.11.2 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications
13.11.3 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 PROBIOMED Main Business Overview
13.11.5 PROBIOMED Latest Developments
13.12 Shanghai Pharmaceuticals Holding Co., Ltd.
13.12.1 Shanghai Pharmaceuticals Holding Co., Ltd. Company Information
13.12.2 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications
13.12.3 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Shanghai Pharmaceuticals Holding Co., Ltd. Main Business Overview
13.12.5 Shanghai Pharmaceuticals Holding Co., Ltd. Latest Developments
14 Research Findings and Conclusion
List of Tables Table 1. Tumor Necrosis Factor Inhibitor Drug Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions) Table 2. Tumor Necrosis Factor Inhibitor Drug Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions) Table 3. Major Players of Humira Table 4. Major Players of Enbrel Table 5. Major Players of Remicade Table 6. Major Players of Simponi Table 7. Major Players of Cimzia Table 8. Major Players of Biosimilars Table 9. Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2019-2024) & (K Units) Table 10. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2019-2024) Table 11. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Type (2019-2024) & ($ million) Table 12. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2019-2024) Table 13. Global Tumor Necrosis Factor Inhibitor Drug Sale Price by Type (2019-2024) & (US$/Unit) Table 14. Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2019-2024) & (K Units) Table 15. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2019-2024) Table 16. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Application (2019-2024) Table 17. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application (2019-2024) Table 18. Global Tumor Necrosis Factor Inhibitor Drug Sale Price by Application (2019-2024) & (US$/Unit) Table 19. Global Tumor Necrosis Factor Inhibitor Drug Sales by Company (2019-2024) & (K Units) Table 20. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Company (2019-2024) Table 21. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Company (2019-2024) ($ Millions) Table 22. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Company (2019-2024) Table 23. Global Tumor Necrosis Factor Inhibitor Drug Sale Price by Company (2019-2024) & (US$/Unit) Table 24. Key Manufacturers Tumor Necrosis Factor Inhibitor Drug Producing Area Distribution and Sales Area Table 25. Players Tumor Necrosis Factor Inhibitor Drug Products Offered Table 26. Tumor Necrosis Factor Inhibitor Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) Table 27. New Products and Potential Entrants Table 28. Mergers & Acquisitions, Expansion Table 29. Global Tumor Necrosis Factor Inhibitor Drug Sales by Geographic Region (2019-2024) & (K Units) Table 30. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share Geographic Region (2019-2024) Table 31. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Geographic Region (2019-2024) & ($ millions) Table 32. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Geographic Region (2019-2024) Table 33. Global Tumor Necrosis Factor Inhibitor Drug Sales by Country/Region (2019-2024) & (K Units) Table 34. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country/Region (2019-2024) Table 35. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Country/Region (2019-2024) & ($ millions) Table 36. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country/Region (2019-2024) Table 37. Americas Tumor Necrosis Factor Inhibitor Drug Sales by Country (2019-2024) & (K Units) Table 38. Americas Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2019-2024) Table 39. Americas Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2019-2024) & ($ Millions) Table 40. Americas Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2019-2024) Table 41. Americas Tumor Necrosis Factor Inhibitor Drug Sales by Type (2019-2024) & (K Units) Table 42. Americas Tumor Necrosis Factor Inhibitor Drug Sales by Application (2019-2024) & (K Units) Table 43. APAC Tumor Necrosis Factor Inhibitor Drug Sales by Region (2019-2024) & (K Units) Table 44. APAC Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region (2019-2024) Table 45. APAC Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2019-2024) & ($ Millions) Table 46. APAC Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Region (2019-2024) Table 47. APAC Tumor Necrosis Factor Inhibitor Drug Sales by Type (2019-2024) & (K Units) Table 48. APAC Tumor Necrosis Factor Inhibitor Drug Sales by Application (2019-2024) & (K Units) Table 49. Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country (2019-2024) & (K Units) Table 50. Europe Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2019-2024) Table 51. Europe Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2019-2024) & ($ Millions) Table 52. Europe Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2019-2024) Table 53. Europe Tumor Necrosis Factor Inhibitor Drug Sales by Type (2019-2024) & (K Units) Table 54. Europe Tumor Necrosis Factor Inhibitor Drug Sales by Application (2019-2024) & (K Units) Table 55. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country (2019-2024) & (K Units) Table 56. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2019-2024) Table 57. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2019-2024) & ($ Millions) Table 58. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2019-2024) Table 59. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales by Type (2019-2024) & (K Units) Table 60. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales by Application (2019-2024) & (K Units) Table 61. Key Market Drivers & Growth Opportunities of Tumor Necrosis Factor Inhibitor Drug Table 62. Key Market Challenges & Risks of Tumor Necrosis Factor Inhibitor Drug Table 63. Key Industry Trends of Tumor Necrosis Factor Inhibitor Drug Table 64. Tumor Necrosis Factor Inhibitor Drug Raw Material Table 65. Key Suppliers of Raw Materials Table 66. Tumor Necrosis Factor Inhibitor Drug Distributors List Table 67. Tumor Necrosis Factor Inhibitor Drug Customer List Table 68. Global Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Region (2025-2030) & (K Units) Table 69. Global Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Region (2025-2030) & ($ millions) Table 70. Americas Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Country (2025-2030) & (K Units) Table 71. Americas Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Country (2025-2030) & ($ millions) Table 72. APAC Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Region (2025-2030) & (K Units) Table 73. APAC Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Region (2025-2030) & ($ millions) Table 74. Europe Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Country (2025-2030) & (K Units) Table 75. Europe Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Country (2025-2030) & ($ millions) Table 76. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Country (2025-2030) & (K Units) Table 77. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Country (2025-2030) & ($ millions) Table 78. Global Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Type (2025-2030) & (K Units) Table 79. Global Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Type (2025-2030) & ($ Millions) Table 80. Global Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Application (2025-2030) & (K Units) Table 81. Global Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Application (2025-2030) & ($ Millions) Table 82. AbbVie Inc. Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors Table 83. AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications Table 84. AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 85. AbbVie Inc. Main Business Table 86. AbbVie Inc. Latest Developments Table 87. Amgen Inc. Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors Table 88. Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications Table 89. Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 90. Amgen Inc. Main Business Table 91. Amgen Inc. Latest Developments Table 92. Johnson & Johnson Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors Table 93. Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications Table 94. Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 95. Johnson & Johnson Main Business Table 96. Johnson & Johnson Latest Developments Table 97. UCB Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors Table 98. UCB Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications Table 99. UCB Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 100. UCB Main Business Table 101. UCB Latest Developments Table 102. Novartis AG Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors Table 103. Novartis AG Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications Table 104. Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 105. Novartis AG Main Business Table 106. Novartis AG Latest Developments Table 107. Pfizer, Inc. Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors Table 108. Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications Table 109. Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 110. Pfizer, Inc. Main Business Table 111. Pfizer, Inc. Latest Developments Table 112. Merck & Co., Inc. Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors Table 113. Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications Table 114. Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 115. Merck & Co., Inc. Main Business Table 116. Merck & Co., Inc. Latest Developments Table 117. CASI Pharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors Table 118. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications Table 119. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 120. CASI Pharmaceuticals Main Business Table 121. CASI Pharmaceuticals Latest Developments Table 122. EPIRUS Biopharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors Table 123. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications Table 124. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 125. EPIRUS Biopharmaceuticals Main Business Table 126. EPIRUS Biopharmaceuticals Latest Developments Table 127. LEO Pharma Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors Table 128. LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications Table 129. LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 130. LEO Pharma Main Business Table 131. LEO Pharma Latest Developments Table 132. PROBIOMED Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors Table 133. PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications Table 134. PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 135. PROBIOMED Main Business Table 136. PROBIOMED Latest Developments Table 137. Shanghai Pharmaceuticals Holding Co., Ltd. Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors Table 138. Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product Portfolios and Specifications Table 139. Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 140. Shanghai Pharmaceuticals Holding Co., Ltd. Main Business Table 141. Shanghai Pharmaceuticals Holding Co., Ltd. Latest Developments List of Figures Figure 1. Picture of Tumor Necrosis Factor Inhibitor Drug Figure 2. Tumor Necrosis Factor Inhibitor Drug Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Tumor Necrosis Factor Inhibitor Drug Sales Growth Rate 2019-2030 (K Units) Figure 7. Global Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate 2019-2030 ($ Millions) Figure 8. Tumor Necrosis Factor Inhibitor Drug Sales by Region (2019, 2023 & 2030) & ($ Millions) Figure 9. Product Picture of Humira Figure 10. Product Picture of Enbrel Figure 11. Product Picture of Remicade Figure 12. Product Picture of Simponi Figure 13. Product Picture of Cimzia Figure 14. Product Picture of Biosimilars Figure 15. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type in 2023 Figure 16. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2019-2024) Figure 17. Tumor Necrosis Factor Inhibitor Drug Consumed in Rheumatoid Arthritis Figure 18. Global Tumor Necrosis Factor Inhibitor Drug Market: Rheumatoid Arthritis (2019-2024) & (K Units) Figure 19. Tumor Necrosis Factor Inhibitor Drug Consumed in Psoriatic Arthritis Figure 20. Global Tumor Necrosis Factor Inhibitor Drug Market: Psoriatic Arthritis (2019-2024) & (K Units) Figure 21. Tumor Necrosis Factor Inhibitor Drug Consumed in Juvenile Idiopathic Arthritis Figure 22. Global Tumor Necrosis Factor Inhibitor Drug Market: Juvenile Idiopathic Arthritis (2019-2024) & (K Units) Figure 23. Tumor Necrosis Factor Inhibitor Drug Consumed in Crohn’s Disease Figure 24. Global Tumor Necrosis Factor Inhibitor Drug Market: Crohn’s Disease (2019-2024) & (K Units) Figure 25. Tumor Necrosis Factor Inhibitor Drug Consumed in Ulcerative Colitis Figure 26. Global Tumor Necrosis Factor Inhibitor Drug Market: Ulcerative Colitis (2019-2024) & (K Units) Figure 27. Tumor Necrosis Factor Inhibitor Drug Consumed in Others Figure 28. Global Tumor Necrosis Factor Inhibitor Drug Market: Others (2019-2024) & (K Units) Figure 29. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2023) Figure 30. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application in 2023 Figure 31. Tumor Necrosis Factor Inhibitor Drug Sales Market by Company in 2023 (K Units) Figure 32. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Company in 2023 Figure 33. Tumor Necrosis Factor Inhibitor Drug Revenue Market by Company in 2023 ($ Million) Figure 34. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Company in 2023 Figure 35. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Geographic Region (2019-2024) Figure 36. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Geographic Region in 2023 Figure 37. Americas Tumor Necrosis Factor Inhibitor Drug Sales 2019-2024 (K Units) Figure 38. Americas Tumor Necrosis Factor Inhibitor Drug Revenue 2019-2024 ($ Millions) Figure 39. APAC Tumor Necrosis Factor Inhibitor Drug Sales 2019-2024 (K Units) Figure 40. APAC Tumor Necrosis Factor Inhibitor Drug Revenue 2019-2024 ($ Millions) Figure 41. Europe Tumor Necrosis Factor Inhibitor Drug Sales 2019-2024 (K Units) Figure 42. Europe Tumor Necrosis Factor Inhibitor Drug Revenue 2019-2024 ($ Millions) Figure 43. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales 2019-2024 (K Units) Figure 44. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Revenue 2019-2024 ($ Millions) Figure 45. Americas Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country in 2023 Figure 46. Americas Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country in 2023 Figure 47. Americas Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2019-2024) Figure 48. Americas Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2019-2024) Figure 49. United States Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 50. Canada Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 51. Mexico Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 52. Brazil Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 53. APAC Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region in 2023 Figure 54. APAC Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Regions in 2023 Figure 55. APAC Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2019-2024) Figure 56. APAC Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2019-2024) Figure 57. China Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 58. Japan Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 59. South Korea Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 60. Southeast Asia Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 61. India Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 62. Australia Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 63. China Taiwan Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 64. Europe Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country in 2023 Figure 65. Europe Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country in 2023 Figure 66. Europe Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2019-2024) Figure 67. Europe Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2019-2024) Figure 68. Germany Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 69. France Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 70. UK Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 71. Italy Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 72. Russia Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 73. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country in 2023 Figure 74. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country in 2023 Figure 75. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2019-2024) Figure 76. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2019-2024) Figure 77. Egypt Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 78. South Africa Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 79. Israel Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 80. Turkey Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 81. GCC Country Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2019-2024 ($ Millions) Figure 82. Manufacturing Cost Structure Analysis of Tumor Necrosis Factor Inhibitor Drug in 2023 Figure 83. Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitor Drug Figure 84. Industry Chain Structure of Tumor Necrosis Factor Inhibitor Drug Figure 85. Channels of Distribution Figure 86. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Forecast by Region (2025-2030) Figure 87. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share Forecast by Region (2025-2030) Figure 88. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share Forecast by Type (2025-2030) Figure 89. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share Forecast by Type (2025-2030) Figure 90. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share Forecast by Application (2025-2030) Figure 91. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share Forecast by Application (2025-2030)
